Endostatin: Yeast production, mutants, and antitumor effect in renal cell carcinoma

Cancer Research

Volumn 59, Issue 1, 1999, Pages 189-197

  Dhanabal, Mohanraj ^a   Ramchandran, Ramani ^a   Volk, Ruediger ^a   Stillman, Isaac E ^a   Lombardo, Michelle ^a   Iruela Arispe, M L ^a   Simons, Michael ^a   Sukhatme, Vikas P ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOSTATIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; DRUG PURIFICATION; DRUG SYNTHESIS; ENDOTHELIUM CELL; KIDNEY CARCINOMA; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; YEAST;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CATTLE; COLLAGEN; COLLAGEN TYPE XVIII; ENDOSTATINS; KIDNEY NEOPLASMS; MICE; MUTATION; NEOPLASMS, EXPERIMENTAL; PEPTIDE FRAGMENTS; RABBITS; RECOMBINANT PROTEINS; SACCHAROMYCES CEREVISIAE; TUMOR CELLS, CULTURED;

EID: 0032894131     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Mulders, P., Figlin, R., deKernion, J. B., Wiltrout, R., Linehan, M., Parkinson, D., deWolf, W., and Belldegrun, A. Renal cell carcinoma: recent progress and future directions. Cancer Res., 57: 5189-5195, 1997.
2. Maher, E. R., and Kaelin, W. G., Jr. von Hippel-Lindau disease. Medicine (Baltimore), 76: 381-391, 1997.
3. Mukhopadhyay, D., Knebelmann, B., Cohen, H. T., Ananth, S., and Sukhatme, V. P. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol. Cell. Biol., 17: 5629-5639, 1997.
4. Gnarra, J. R., Zhou, S., Merrill, M. J., Wagner, J. R., Krumm, A., Papavassiliou, E., Oldfield, E. H., Klausner, R. D., and Linehan, W. M. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc. Natl. Acad. Sci. USA. 93: 10589-10594, 1996.
5. Iliopoulos, O., Levy, A. P., Jiang, C., Kaelin, W. G. J., and Goldberg, M. A. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. USA. 93: 10595-10599, 1996.
6. Siemeister, G., Weindel, K., Mohrs, K., Barleon, B., Martiny-Baron, G., and Marme, D. Revision of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res., 56: 2299-2301, 1996.
7. Iliopoulos, O., Kibel, A., Gray, S., and Kaelin, W. G., Jr. Tumour suppression by the human von Hippel-Lindau gene product. Nat. Med., I: 822-826, 1995.
8. Baillie, C. T., Winslet, M. C., and Bradley, N. J. Tumour vasculature-a potential therapeutic target. Br. I. Cancer. 72: 257-267, 1995.
9. Bicknell, R. Vascular targeting and the inhibition of angiogenesis. Ann. Oncol., 5 (Suppl. 4): 45-50, 1994.
10. Fan, T. P., Jaggar, R., and Bicknell, R. Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy. Trends Pharmacol. Sci., 16: 57-66, 1995.
11. Thorpe, P. E., and Burrows, F. J. Antibody-directed targeting of the vasculature of solid tumors [see comments]. Breast Cancer Res. Treat., 36: 237-251, 1995.
12. Burrows, F. J., and Thorpe, P. E. Vascular targeting-a new approach to the therapy of solid tumors. Pharmacol. Ther., 64: 155-174, 1994.
13. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 285: 1182-1186, 1971.
14. Folkman, J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann. Surg., 175: 409-416, 1972.
15. Folkman, J., and Shing, Y. Angiogenesis. J. Biol. Chem., 267: 10931-10934, 1992.
16. Folkman, J. Fighting cancer by attacking its blood supply. Sci. Am., 275: 150-154, 1996.
17. Maione, T. E., Gray, G. S., Petro, J., Hunt, A. J., Donner, A. L., Bauer, S. J., Carson, H. F., and Sharpe, R. J. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science (Washington DC), 247: 77-79, 1990.
18. Gupta, S. K., Hassel, T., and Singh, J. P. A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4. Proc. Natl. Acad. Sci. USA, 92: 7799-7803, 1995.
19. Angiolillo, A. L., Sgadari, C., Taub, D. D., Liao, F., Farber, J. M., Maheshwari, S., Kleinman, H. K., Reaman, G. H., and Tosato, G. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J. Exp. Med., 182: 155-162, 1995.
20. Strieter, R. M., Kunkel, S. L., Arenberg, D. A., Burdick, M. D., and Polverini, P. J. Interferon gamma-inducible protein 10 (1P-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem. Biophys. Res. Commun., 210: 51-57, 1995.
21. Brooks, P. C., Silletti, S., von Schalscha, T. L., Friedlander, M., and Cheresh, D. A. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell, 92: 391-400, 1998.
22. O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H., and Folkman, J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma [see comments]. Cell, 79: 315-328, 1994.
23. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277-285, 1997.
24. Dong, Z., Kumar, R., Yang, X., and Fidler, I. J. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell, 88: 801-810, 1997.
25. Lannutti, B. J., Gately, S. T., Quevedo, M. E., Soff, G. A., and Paller, A. S. Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo. Cancer Res., 57: 5277-5280, 1997.
26. O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Cao, Y., Moses, M., Lane, W. S., Sage, E. H., and Folkman, J. Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harb. Symp. Quant. Biol., 59: 471-482, 1994.
27. O'Reilly, M. S. Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. Exper. Suppl. (Basel), 79: 273-294, 1997.
28. Sim, B. K., O'Reilly, M. S., Liang, H., Fortier, A. H., He, W., Madsen, J. W., Lapcevich, R., and Nacy, C. A. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res., 57: 1329-1334, 1997.
29. Wu, Z., O'Reilly, M. S., Folkman, J., and Shing, Y. Suppression of tumor growth with recombinant murine angiostatin. Biochem. Biophys. Res. Commun., 236: 651-654, 1997.
30. Standker, L., Schrader, M., Kanse, S. M., Jurgens, M., Forssmann, W. G. and Preissner, K. T. Isolation and characterization of the circulating form of human endostatin. FEBS Lett., 420, 129-133, 1997.
31. Boehm, T., Folkman, J., Browder, T., and O'Reilly, M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance [see comments]. Nature (Lond.), 390: 404-407, 1997.
32. Kerbel, R. S. A cancer therapy resistant to resistance. Nature (Lond.), 390: 335-336, 1997.
33. Eckart, M. R., and Bussineau, C. M. Quality and authenticity of heterologous proteins synthesized in yeast. Curr. Opin. Biotechnol., 7: 525-530, 1996.
34. Cregg, J. M., Vedvick, T. S., and Raschke, W. C. Recent advances in the expression of foreign genes in Pichia pastoris. Biotechnology (NY), 8: 905-910, 1993.
35. Dhanabal, M., Fryxell, D. K., and Ramakrishnan, S. A novel method to purify immunotoxins from free antibodies using modified recombinant toxins. J. Immunol. Methods, 182: 165-175, 1995.
36. Iruela-Arispe, M. L., and Dvorak, H. F. Angiogenesis: a dynamic balance of stimulators and inhibitors. Thromb. Haemost., 78: 672-677, 1997.
37. Fleer, R. Engineering yeast for high level expression. Curr. Opin. Biotechnol., 3: 486-496, 1992.
38. Sudbery, P. E. The expression of recombinant proteins in yeasts. Curr. Opin. Biotechnol., 7: 517-524, 1996.
39. Mauceri, H. J., Hanna, N. N., Beckett, M. A., Gorski, D. H., Staba, M-J., Stellato, K. A., Bigelow, K., Heimann, R., Gately, S., Dhanabal, M., Soff, G. A., Sukhatme, V. P., Kufe, D. W., and Weichselbaum, R. R. Interaction of angiostatin and ionizing radiation in anti-tumour therapy. Nature, 394: 287-291, 1998.
40. Hohenester, E., Sasaki, T., Olsen, B. R., and Timpl, R. Crystal structure of the angiogenesis inhibitor endostatin al 1.5 Å resolution. EMBO J., 17: 1656-1664, 1998.
41. Rehn, M., and Pihlajaniemi, T. Alpha 1(XVIII), a collagen chain with frequent interruptions in the collagenous sequence, a distinct tissue distribution, and homology with type XV collagen. Proc. Natl. Acad. Sci. USA, 91: 4234-4238, 1994.
42. Muragaki, Y., Timmons, S., Griffith, C. M., Oh, S. P., Fadel, B., Quertermous, T., and Olsen, B. R. Mouse Coll8a1 is expressed in a tissue-specific manner as three alternative variants and is localized in basement membrane zones. Proc. Natl. Acad. Sci. USA, 92: 8763-8767, 1995.
43. Re, F., Zanetti, A., Sironi, M., Polentarutti, N., Lanfrancone, L., Dejana, E., and Colotta, F. Inhibition of anchorage-dependent cell spreading triggers apoptosis in cultured human endothelial cells. J. Cell Biol., 127: 537-546, 1994.